Wall Street analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to announce earnings of ($0.17) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.19). Aptose Biosciences posted earnings of ($0.23) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 26.1%. The business is expected to announce its next earnings report on Thursday, May 9th.
According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.69). For the next fiscal year, analysts expect that the firm will post earnings of ($0.82) per share, with EPS estimates ranging from ($0.94) to ($0.72). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Aptose Biosciences.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01).
NASDAQ:APTO traded down $0.02 during trading hours on Friday, hitting $1.83. 103,226 shares of the company traded hands, compared to its average volume of 273,304. Aptose Biosciences has a one year low of $1.57 and a one year high of $4.55. The stock has a market cap of $73.66 million, a PE ratio of -2.13 and a beta of 1.61.
In other Aptose Biosciences news, CFO Gregory K. Chow bought 15,000 shares of the stock in a transaction dated Wednesday, March 13th. The shares were bought at an average cost of $1.75 per share, for a total transaction of $26,250.00. Following the purchase, the chief financial officer now directly owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Erich Platzer sold 20,000 shares of Aptose Biosciences stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 35,000 shares of company stock worth $63,750.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Aptose Biosciences during the 1st quarter worth $198,000. Geode Capital Management LLC bought a new stake in shares of Aptose Biosciences during the 4th quarter worth $33,000. Noven Financial Group Inc. bought a new stake in shares of Aptose Biosciences during the 4th quarter worth $27,000. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Aptose Biosciences by 11.4% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 5,890 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Aptose Biosciences by 1,130.9% during the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 168,501 shares during the period. Institutional investors own 7.68% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.